NCT03841617 2026-02-17
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
24 trialsNCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT06980103 2026-01-08
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
Georgetown University
Phase NA Recruiting
NCT00673010 2025-10-09
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03215095 2025-07-17
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05142904 2025-07-17
RABITO
Rijnstate Hospital
Phase 3 Terminated
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT04354324 2024-03-15
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Zhujiang Hospital
Phase NA Recruiting
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT05468554 2022-10-19
METHYR
Medical University of Bialystok
Phase 3 Not yet recruiting
NCT04952493 2022-01-28
Anlotinib or Penpulimab in Combination With RAI for DTC
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04876287 2021-05-10
START
Institut de Radioprotection et de Surete Nucleaire
Completed
NCT04072731 2019-08-28
SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer
People's Hospital of Zhengzhou University
Completed
NCT03624751 2018-08-10
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Taichung Veterans General Hospital
Recruiting
NCT00115895 2018-03-02
The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy
University of Helsinki
Phase 3 Unknown
NCT02375451 2017-06-26
Effect of Childhood Radioiodine Therapy on Salivary Function
Boston Children's Hospital
Completed
NCT02418247 2017-01-20
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
National Cancer Center, Korea
Phase 2/3 Unknown
NCT01413113 2015-11-05
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
University of Washington
Phase 1 Completed
NCT00196729 2015-03-18
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Sanofi
Phase 3 Completed
NCT00004062 2013-12-19
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01150318 2013-08-07
SAPIRA
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT00439478 2007-11-14
Dental Safety Profile of High-Dose Radioiodine Therapy
University Hospital, Basel, Switzerland
Completed